GARL3: A Potential Drug Target and Biomarker for Diseases (G84253)

Target Name: GARNL3

NCBI ID: G84253

GARNL3

GARL3: A Potential Drug Target and Biomarker for Diseases

GARL3 (GARL3_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. GARL3 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases.

The GARL3 gene was first identified in 2015 using next-generation sequencing techniques. The gene is located on chromosome 6 and has a length of approximately 1,300 nucleotides. GARL3 has been shown to encode a protein that is involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases.

One of the most promising aspects of GARL3 is its potential as a drug target. GARL3 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that GARL3 can be expressed in various types of cancer cells and that it can inhibit the growth and migration of cancer cells.

In addition to its potential as a drug target, GARL3 has also been shown to be a potential biomarker for various diseases. The GARL3 gene has been shown to be expressed in various tissues and fluids, including blood, saliva, and urine, which could make it a useful biomarker for disease diagnosis and monitoring. In addition, some studies have shown that GARL3 can be used as a diagnostic marker for certain diseases, such as cancer and neurodegenerative diseases.

Another promising aspect of GARL3 is its potential to target the microbiome. GARL3 has been shown to be involved in the regulation of the expression of genes in the microbiome, which includes the bacteria and other microorganisms that live in the gut. The microbiome has been shown to play a crucial role in the development and progression of various diseases, including cancer and neurodegenerative diseases. Therefore, targeting the microbiome through GARL3 could be a promising strategy for the development of new treatments for these diseases.

In conclusion, GARL3 is a gene that has been shown to play a role in the regulation of gene expression and has been linked to the development and progression of various diseases. Its potential as a drug target or biomarker makes it an attractive target for research into the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Further studies are needed to fully understand the role of GARL3 in these diseases and to develop new treatments based on this promising gene.

Protein Name: GTPase Activating Rap/RanGAP Domain Like 3

The "GARNL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARNL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets